Compare Johnson & Johnson (JNJ) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Schwab US Large Cap Growth ETF — how do they compare? Johnson & Johnson trades at $249.39 (market cap $598.96B), while Schwab US Large Cap Growth ETF trades at $34.28. The key difference: Johnson & Johnson pays a 2.15% dividend while Schwab US Large Cap Growth ETF pays none. Which is the better fit depends on your goals.
| JNJ | SCHG | |
|---|---|---|
Market Cap | $598.96B | — |
Volume | 6,156,228 | — |
Sector | Health | Sector/Thematic |
52-Week High | $267.24 | $35.30 |
52-Week Low | $164.36 | $28.10 |
Enterprise Value | $631.90B | — |
Dividend Yield | 2.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
SCHG trades at $34.15, down slightly by 0.09% today, with a bullish technical signal driven by moving averages. The ETF offers concentrated exposure to large-cap U.S. growth stocks, particularly in technology and AI, with a low 0.04% expense ratio. Recent news highlights strong fundamentals and AI-driven growth potential, though heavy concentration in top holdings like Nvidia, Apple, and Microsoft presents both opportunity and risk.
Outlook remains positive for long-term growth investors, supported by AI capital expenditure trends and low costs. Key risks include high valuation sensitivity, interest rate impacts, and lack of diversification. Analyst sentiment is mixed, with some caution on recent underperformance versus broader markets despite strong thematic tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
